How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/onychomycosis-due-to-dermatophyte.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Onychomycosis due to dermatophyte — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Onychomycosis due to dermatophyte (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Onychomycosis due to dermatophyte, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Jublia	EFINACONAZOLE	Bausch Health	Azole Antifungal [EPC]		2014-01-01
Loprox	CICLOPIROX	Bausch Health	ciclopirox	Poly [ADP-ribose] polymerase 1	1982-01-01
Monistat	miconazole	Johnson & Johnson (Janssen)	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01
Grifulvin V	GRISEOFULVIN	Johnson And Johnson	Tubulin Inhibiting Agent [EPC]	Solute carrier family 22 member 1	1962-01-01
GRISACTIN ULTRA	GRISEOFULVIN, ULTRAMICROCRYSTALLINE	WYETH AYERST		Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
FULVICIN P/G 330	GRISEOFULVIN, ULTRAMICROSIZE	CHARTWELL RX		Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
GRISEOFULVIN	GRISEOFULVIN, MICROSIZE	COSETTE	Tubulin Inhibiting Agent [EPC]	Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
GRIFULVIN V	GRISEOFULVIN, MICROCRYSTALLINE	JOHNSON AND JOHNSON		Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin
Penlac	Penlac	9305-9954 Quebec Inc		Deoxyhypusine hydroxylase, Poly [ADP-ribose] polymerase 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Bausch Health · 2 drugs in Onychomycosis due to dermatophyte
CHARTWELL RX · 1 drug in Onychomycosis due to dermatophyte
COSETTE · 1 drug in Onychomycosis due to dermatophyte
JOHNSON AND JOHNSON · 1 drug in Onychomycosis due to dermatophyte
Johnson & Johnson (Janssen) · 1 drug in Onychomycosis due to dermatophyte
Johnson And Johnson · 1 drug in Onychomycosis due to dermatophyte
9305-9954 Quebec Inc · 1 drug in Onychomycosis due to dermatophyte
WYETH AYERST · 1 drug in Onychomycosis due to dermatophyte

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Onychomycosis due to dermatophyte:

Cite this brief

Drug Landscape (2026). Onychomycosis due to dermatophyte — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/onychomycosis-due-to-dermatophyte. Accessed 2026-06-10.

Onychomycosis due to dermatophyte full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing